The Future of Alzheimer's Research Starts With You

See the difference: learn more about how pTau plays a role in Alzheimer's Disease


Biomarkers are playing an increasingly important role in the diagnosis of Alzheimer’s disease.

The FDA has recently published guidelines that endorse their use5, and the National Institute on Aging—Alzheimer’s Association (NIA-AA) has created a research framework that defines Alzheimer’s disease as a biological process characterized by associated biomarkers6. These steps have the potential to evolve Alzheimer’s Disease (AD) diagnostics from a clinically based diagnosis of exclusion to a biological basis that relies on biomarkers in a context of supporting clinical evidence.

In AD, tau protein, contained within neurons, is abnormally phosphorylated and aggregated into bundles of filaments. There are pathological hallmarks, specifically the presence of intracellular neurofibrillary tangles2, which are formed by the abnormal accumulation of hyperphosphorylated tau protein and can be detected 10-15 years before symptom onset3,4. Threonine 181 is one of the phosphorylation sites of human tau protein (pTau181) and is a specific biomarker for AD. pTau181 has been found to be more strongly associated with markers of AD than total tau and can be detected in both the CSF and plasma of patients.

Learn more about pTau

Our Current Portfolio

Quanterix currently offers several options for screening pTau biomarkers in samples.

pTau Assay Kits

Our array of ready-to-use Simoa® kits for pTau181, pTau231 and total Tau contain all the reagents necessary to run your assay on a range of Quanterix instruments.

Simoa® Accelerator Laboratory

Utilize our CLIA-Certified laboratory as a cost-effective outsourced solution for your custom biomarker and biopharmaceutical research, assay development, and clinical sample testing.

Coming soon: pTau217

We will soon be able to offer early access to pTau217, another critical biomarker for AD research. Be added to our notification list for earl-access now.

Drive your Alzheimer's Disease research forward with pTau181

Powered by Simoa® Technology

 

Simoa assays can help researches with a strategic focus in neurodegeneration, neuroinflammation, traumatic brain injuries (TBI) and multiple sclerosis (MS) to drive advancements in cognitive health research. 

Quanterix has built key partners throughout the Alzheimer's research landscape, from academic institutions to biotechnology and pharmaceutical firms to drive forward advancements in brain health research.

To gain access to these innovative health research solutions, request more information today.